<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3342">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04275388</url>
  </required_header>
  <id_info>
    <org_study_id>QF-XYP2001-1</org_study_id>
    <nct_id>NCT04275388</nct_id>
  </id_info>
  <brief_title>Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia</brief_title>
  <official_title>Retrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the investigators conduct a randomized, open-label trial to evaluate and compare the safety
      and efficacy of Xiyanping injection in patients with 2019-nCoV pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2020</start_date>
  <completion_date type="Anticipated">December 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical recovery time</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>From the beginning of study drug use to fever, respiratory rate, blood oxygen saturation to normal and cough relief, and maintained for at least 72 hours or more, calculated in hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete fever time</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>From the beginning of research drug use to body temperature &lt;37.3 ℃ (underarm) or mouth temperature ≤37.5 ° C, or anal or ear temperature ≤37.8 ° C, and maintained for 24h or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough relief time</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Cough score &quot;day + night&quot; from the beginning of study medication to cough ≤ 1 point, and maintained for 24 hours and above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virus negative time</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>From the beginning of the study drug to two consecutive times (sampling interval of at least 1 day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe or critical neocoronavirus pneumonia</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Defined as the proportion of subjects exacerbated during treatment and meeting the diagnostic criteria for severe or critical neocoronavirus pneumonia</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">426</enrollment>
  <condition>2019 Novel Coronavirus Pneumonia</condition>
  <arm_group>
    <arm_group_label>Xiyanping injection +other drugs</arm_group_label>
    <description>Drug: Xiyanping injection Xiyanping injection: 10-20ml daily, Qd, the maximum daily dose does not exceed 500mg (20mL) Other drugs: Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>other drugs</arm_group_label>
    <description>Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiyanping injection</intervention_name>
    <description>Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,</description>
    <arm_group_label>Xiyanping injection +other drugs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride</intervention_name>
    <description>Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride</description>
    <arm_group_label>Xiyanping injection +other drugs</arm_group_label>
    <arm_group_label>other drugs</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      routine blood test
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with new coronary pneumonia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Laboratory examination (RT-PCR) confirms the infection 2019-nCoV, which meets the
             diagnostic criteria for pneumonia (common type) in the New Coronavirus Infection
             Pneumonia Diagnosis and Treatment Program (Trial Version 6);

          2. The patient has a complete hospitalization record that can be used for research.

        Exclusion Criteria:

        -

        Subjects who meet any of the following criteria cannot be enrolled:

          1. Suffering from diseases that need to be distinguished from pneumonia infected with new
             coronavirus, such as tuberculosis, bacterial or viral pneumonia other than new
             coronavirus pneumonia, hospital-acquired pneumonia, and other pathogenic
             microorganisms pneumonia;

          2. People with basic diseases such as primary immunodeficiency disease, acquired
             immunodeficiency syndrome, congenital respiratory tract malformations, abnormal lung
             development, aspiration pneumonia, and lung malignant tumors;

          3. According to the judgment of the investigator, the previous or current disease may
             affect the patient's participation in the trial or the outcome of the study,
             including: malignant disease, autoimmune disease, liver and kidney disease, blood
             disease, neurological disease, and endocrine Disease; presently suffering from
             diseases that seriously affect the immune system, such as: human immunodeficiency
             virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc;

          4. Pneumonia diagnosed with severe, critically re-associated coronavirus infection or
             requiring mechanical ventilation or systemic anti-hormonal therapy;

          5. Used Chinese patent medicines with similar efficacy as Xiyanping injection during the
             treatment.

          6. The investigator judges that the relevant test or data is missing during the treatment
             process, which affects the research evaluation or analyst.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongzhou Lu, Master</last_name>
    <phone>021-37990333</phone>
    <email>lunliweiyuanhui2009@126.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>May 17, 2020</last_update_submitted>
  <last_update_submitted_qc>May 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

